Sanofi, Regeneron win FDA nod for once-monthly cholesterol injection

Sanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) said today that the FDA approved the companies’ new supplemental Biologics License Application for a once-monthly, 300 milligram dose of Praluent as a treatment for adults with high low-density lipoprotein cholesterol.

The 300 milligram dose is administered using 2 pre-filled pens that each deliver 150 milligrams at an injection site. The European Commission approved the once-monthly dose of Praluent (alirocumab) in November last year, Sanofi said.

Get the full story at our sister site, Drug Delivery Business News.

The post Sanofi, Regeneron win FDA nod for once-monthly cholesterol injection appeared first on MassDevice.

from MassDevice http://ift.tt/2oHrACA